Case reports highlight varied clinical courses in autoimmune haemolytic anaemia, indicating challenges in diagnosis and treatment.
Autoimmune Haemolytic Anaemia (AIHA) is a rare yet serious condition characterized by immune-mediated red cell destruction. It presents with anaemia, jaundice, and splenomegaly, requiring a high index of suspicion for timely diagnosis. We present two cases managed at the Kenyatta National Hospital (KNH), highlighting varied disease courses and treatment responses. Management includes corticosteroids as first-line therapy, with immunosuppressants or biologics like rituximab for refractory cases. Limited access to diagnostic tests and treatment options remains a challenge in Kenya. Addressing these barriers through improved clinician awareness and healthcare infrastructure is crucial for optimizing AIHA outcomes in resource-limited settings.
No takes yet. Share an insight, caveat, or question.
Mutua et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: